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DOI 10.1186/s12888-015-0494-xRESEARCH ARTICLE Open AccessAutism beyond diagnostic categories:
characterization of autistic phenotypes in
schizophrenia
Anne Kästner1, Martin Begemann1,2, Tanja Maria Michel3, Sarah Everts1, Beata Stepniak1, Christiane Bach4,
Luise Poustka4, Joachim Becker1, Tobias Banaschewski4, Matthias Dose5 and Hannelore Ehrenreich1,2*Abstract
Background: Behavioral phenotypical continua from health to disease suggest common underlying mechanisms
with quantitative rather than qualitative differences. Until recently, autism spectrum disorders and schizophrenia
were considered distinct nosologic entities. However, emerging evidence contributes to the blurring of
symptomatic and genetic boundaries between these conditions. The present study aimed at quantifying behavioral
phenotypes shared by autism spectrum disorders and schizophrenia to prepare the ground for biological pathway
analyses.
Methods: Specific items of the Positive and Negative Syndrome Scale were employed and summed up to form a
dimensional autism severity score (PAUSS). The score was created in a schizophrenia sample (N = 1156) and validated in
adult high-functioning autism spectrum disorder (ASD) patients (N = 165). To this end, the Autism Diagnostic Observation
Schedule (ADOS), the Autism (AQ) and Empathy Quotient (EQ) self-rating questionnaires were applied back to back with
the newly developed PAUSS.
Results: PAUSS differentiated between ASD, schizophrenia and a disease-control sample and substantially correlated with
the Autism Diagnostic Observation Schedule. Patients with ADOS scores ≥12 obtained highest, those with scores <7
lowest PAUSS values. AQ and EQ were not found to vary dependent on ADOS diagnosis. ROC curves for ADOS and
PAUSS resulted in AuC values of 0.9 and 0.8, whereas AQ and EQ performed at chance level in the prediction of ASD.
Conclusions: This work underscores the convergence of schizophrenia negative symptoms and autistic phenotypes.
PAUSS evolved as a measure capturing the continuous nature of autistic behaviors. The definition of extreme-groups
based on the dimensional PAUSS may permit future investigations of genetic constellations modulating autistic
phenotypes.
Keywords: Autism spectrum disorders, Positive and negative syndrome scale, Autism diagnostic observation
schedule, Diagnostics, Autism quotient, Empathy quotient, AdultsBackground
Autistic phenotypes transcend diagnostic categories.
Sub-threshold deficits in social communication and re-
stricted interests which do not meet formal criteria for
an autism spectrum disorder (ASD) can be found in the
general population [1-4]. This supports the dimensional* Correspondence: ehrenreich@em.mpg.de
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unless otherwise stated.nature of autistic traits. If surpassing a certain severity
threshold, autistic behaviors may become clinically rele-
vant. Different expressions of autistic phenotypes can
also be observed in patients with psychiatric diagnoses
other than ASD [5].
Particularly, the very heterogeneous diagnostic category
of schizophrenia harbors a distinct subgroup of individuals
with severe autistic features. Historically, autism spectrum
disorders (ASD) and schizophrenia were considered to be
intimately related [6-9]. Based on early epidemiological
studies, they were later conceptualized as distinct diagnostic. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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age of onset [10]. However, boundaries between psychiatric
diagnoses begin to blur. DSM-IV lists 522 criteria for diag-
nosing 201 distinct psychiatric conditions [11,12]. Hence,
several symptoms constitute criteria for more than one dis-
order. Also, genetic risk factors simultaneously associate
with several psychiatric diseases [13-15]. This reflects their
modulating individual behavioral phenotypes instead of
diagnostic categories.
In fact, many patients fulfill criteria for both schizo-
phrenia and an autism spectrum disorder [16-18]. In
both conditions, neuropathological findings support de-
velopmentally altered synaptic connectivity [19-21]. Var-
iations in synaptic genes contribute to the susceptibility
to both disorders [14,22-24]. Neurodevelopmental ab-
normalities typical for children with ASD such as a delay
in motor development, impaired receptive language as
well as relationship and adjustment difficulties are also
found to prevail in individuals later diagnosed with
schizophrenia [25]. Along the same lines, recent studies
convincingly demonstrate that childhood-onset schizo-
phrenia is preceded by an ASD diagnosis in 30%-50% of
the cases [25]. Most importantly, however, among those
suffering from schizophrenia, some exhibit a prominent
autistic phenotype while psychotic symptoms are less
prominent [26,27]. This autistic subgroup of schizo-
phrenic patients can be characterized by difficulties in
social interaction, communication, emotion processing,
and motor abnormalities [27,28]. Schizophrenia patients
predominantly suffering from negative symptoms obtain
high scores on the Autism Diagnostic Observation Sched-
ule (ADOS) [26]. Taken together, the strong phenotypic
relationship suggests overlapping disease mechanisms in-
volved in ASD and at least a subset of schizophrenia
patients.
The present study has been designed to provide a di-
mensional measure for investigations of biological path-
ways common to ASD and the autistic subgroup of
schizophrenia patients. Autistic phenotypes were charac-
terized in schizophrenia patients using items from the
Positive and Negative Syndrome Scale (PANSS) which
has been assessed in the frame of the GRAS data collec-
tion [29,30]. The high internal consistency of all individ-
ual autism variables derived from PANSS encouraged
their aggregation to form a continuous autism severity
score (PANSS autism severity score, PAUSS). As the se-
lected items had not been intended to assess autism-
relevant behaviors, they were subsequently validated in a
sample of high-functioning ASD patients, including pa-
tients with Asperger’s disorder and autistic disorder with
average intellectual functioning (validation sample). By
demonstrating a high convergence of the Autism Diag-
nostic Observation Schedule (ADOS) and the PAUSS,
we illustrate that the latter is suitable for the assessmentof the severity of autistic behaviors in schizophrenia and
high-functioning autism.Methods
Schizophrenia (GRAS) sample
Participants
The present study was approved by the ethics committee
of the Georg-August-University (master committee) and
local internal review boards of collaborating centers. All
patients gave written informed consent. Schizophrenia
diagnoses were made based on DSM-IV-TR criteria [11].
Detailed phenotyping of the GRAS sample [29-31] con-
tained the Positive and Negative Syndrome Scale
(PANSS) [32]. Data analyses were based on 1156 schizo-
phrenia patients (N = 770 male, N = 386 female; referred
to as ‘GRAS sample’ , for detailed information on the
GRAS data collection see [30]).Operationalization of autistic phenotypes in the GRAS
sample –The PANSS autism severity score (PAUSS)
From the thorough phenotype information available in
the GRAS sample [30], items indicative of autistic be-
havior (covering all three symptom domains according
to DSM-IV-TR) [11] were selected from PANSS [32].
The PANSS is a standardized third-party clinical obser-
vation tool, well-evaluated and widely applied to assess
positive, negative, general psychopathology symptom se-
verity in schizophrenia [32]. All raters (psychologists,
psychiatrists) participating in data acquisition for the
GRAS collection over the last 10 years had intensive
trainings, regular consensus meetings, and repeated
interrater reliability testings over the whole GRAS exam-
ination book [30], including PANSS. The severity scoring
of PANSS items ranges from 1 (definition does not
apply) to 7 (severe dysfunction). To cover the ASD diag-
nostic domain of difficulties in social interaction, items 1
(‘blunted affect’); 3 (‘poor rapport’) and 4 (‘social with-
drawal’) of the PANSS negative subscale were used. Dif-
ficulties in communication were measured employing
items 5 (‘difficulties in abstract thinking’) and 6 (‘lack of
spontaneity and flow of conversation’) of the PANSS
negative subscale. The third diagnostic symptom cluster
assessing limited, repetitive and stereotypic patterns of
behavior was accounted for by using item 5 (‘manner-
ism’) and 15 (‘preoccupation’) of the PANSS general sub-
scale and item 7 of the negative subscale (‘stereotyped
thinking’). All individual items were summed up to form
the PANSS autism severity score (PAUSS, range 8 to 56).
Higher PAUS scores represent a higher severity of the
autism phenotype. Extreme-groups (autistic and non-
autistic schizophrenia individuals) include the first
(PAUSS 8-10) and the last percentile (PAUSS 30-52) of
the PAUSS distribution (Figure 1A and B).
AB
Women (N=386)
Men (N=770)
Autistic schizophrenia (N=137, PAUSS: 30-52)
ASD sample (N=148, PAUSS: 8-47)
Non-autistic schizophrenia (N=168, PAUSS: 8-10)
Disease-control sample (N=97, PAUSS: 8-39)
R
el
at
iv
e 
fr
eq
ue
nc
y
PANSS autism severity score (PAUSS) bins
R
el
at
iv
e 
fr
eq
ue
nc
y
PANSS autism severity score (PAUSS) bins
* For nonparametric comparison 
of ASD and other patient groups 
p<.000001
8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52
0.00
0.02
0.04
0.06
0.08
0.10
0.12
8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
*
*
*
0
10
20
30
40
50
60
p=.761
0
10
20
30
40
50
60
P
A
N
S
S
 a
ut
is
m
 s
ev
er
ity
 s
co
re
P
A
N
S
S
 a
ut
is
m
 s
ev
er
ity
 s
co
re
Autistic schizophrenia (N=137)
Non-autistic schizophrenia (N=168)
Figure 1 Distribution of the PANSS autism severity score (PAUSS) in the schizophrenia, ASD and disease-control samples. (A) Relative frequency
distributions of the PAUSS bins in the schizophrenic GRAS sample by gender are shown. The first and last percentile of the distribution (‘autistic
schizophrenics’ and ‘non-autistic schizophrenics’) is contrasted with respect to sociodemographic and clinical characteristics in Table 4. (B)
Comparison of the relative frequency distribution of the PAUSS in the GRAS sample and the validation sample (split into ASD sample and
disease-control sample). Inset figures show means ± SD. All p-values were obtained from Mann-Whitney U-tests.
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Participants
The study was approved by the ethics committee of the
Georg-August-University, Göttingen. All participants
gave written informed consent. A total of 260 adult pa-
tients with an established DSM-IV-TR ASD diagnosis
and 5 cases suspected to suffer from ASD by a health
care professional (practicing clinical psychologists, psy-
chiatrists or specialized German outpatient clinics
personnel) were included (N = 178 male, N = 87 female).
They were recruited from September 2011 to October
2014 via public announcements and collaborations with
specialized autism centers all over Germany. Further
prerequisites for inclusion in the present study were an
IQ ≥ 75 and expressive language skills allowing for the
conductance of a semi-structured interview.
Measures and procedure of the PAUSS validation
Due to the lack of an established diagnostic routine for
ASD in adults in Germany, reliability of ASD diagnoseswas expected to vary depending on the practitioners’ know-
ledge and experience. Therefore, DSM-IV-TR ASD diagno-
ses were confirmed or excluded for all subjects applying the
following procedure: A psychologist (AK) and a psychiatrist
(MB) with together more than 20 years of clinical experi-
ence, both with special training in diagnostics of ASD and
relevant differential diagnoses, examined essentially all pa-
tients. Participants were welcomed by both examiners. A
friendly and casual atmosphere was created, in which spon-
taneous social-communicative behavior could be observed.
Basic information about the medical, social and family his-
tory was recorded. This initial phase was followed by the
conductance of module 4 of the Autism Diagnostic Obser-
vation Schedule (ADOS) [33,34]. Module 4 has been devel-
oped for adolescents and adults with fluent speech and has
good criterion-related validity [26,33,35]. The administra-
tion of ADOS module 4 included all standard and optional
activities. Both ADOS raters of the present study had
undergone a special training to guarantee standardized ad-
ministration and scoring. Additionally, a semi-structured
Table 1 The semi-structured interview for the assessment of developmental history, current daily functioning and
quality of relationships
Given are the interview questions; a detailed psychometrical evaluation of the instrument will be published elsewhere
Part 1: EARLY DEVELOPMENT
Self regulation Has anyone ever told you that you cried a lot when you were an infant and that it was
almost impossible to calm you down?
Has anyone ever told you about feeding problems when you were an infant?
When you were a toddler, did you avoid eating certain things?
Has anyone ever told you that you had difficulties falling asleep or that you could not sleep
through the night?
Motor development How old were you when you started walking?
When you were a child (between 4 and 5 years old), did you enjoy playing ball, doing rope
skipping or other things involving physical exercises?
Which of the following sports did you excel in: Endurance runs, track and field athletics,
climbing, dancing, artistic gymnastics, soccer, basketball, volleyball, team handball,
swimming?
Have you ever practiced any kind of team sports for at least a year? When was that?
Did you like to do things involving fine motor function, e.g. playing Mikado, building card
houses, when you were a child?
Have you ever received occupational therapy, hippotherapy or comparable measures? For
how long?
Speech development At how many months did you speak first words?
At how many months did you speak first two-word-sentences?
Has anybody ever told you that there was something special about the way you talked?
Have you ever had difficulties understanding what other people wanted to tell you?
Have you often been told that you never listened/that you often seemed absent-minded?
Has anyone ever told you that you had a very elaborate vocabulary when you were a child?
Have you ever been treated by a speech therapist?
Part 2: DEVELOPMENT & EDUCATION
Academic performance (proxy for cognitive
development)
How old were you at school enrollment?
Have you ever had to stay down a grade? If yes, which grade?
Have you ever skipped a grade?
Have you ever had difficulties concentrating?
Was there a particular subject or topic that you performed particularly well or poorly at?
Quality of social contacts and activities in childhood,
adolescence and early adulthood
How did you mostly occupy yourself during the school breaks?
How were the kindergarten times for you (age 3 to 6 years)?
Was in the kindergarten something particularly difficult/unpleasant?
What did you like to play in kindergarten times (age 3 to 6 years)?
With whom did you play in kindergarten times (age 3 to 6 years)?
How were the days in elementary school for you (age 6 to 10 years)?
Was there something particularly difficult/unpleasant?
Did you have friends when you were 6 to 10 years old? How many?
What did you like to do in your leisure time when you were 6 to 10 years old?
How were the high school days for you (age 10 to 18 years)?
Did you have friends when you were 10 to 18 years old? How many?
What did you like to do in your leisure time when you were 10 to 18 years old?
Did you suffer from not having friends or from having few friends?
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Table 1 The semi-structured interview for the assessment of developmental history, current daily functioning and
quality of relationships (Continued)
Part 3: CURRENT STATUS
Daily routines Now I am interested in your daily routine. Please describe it to me.
Are there any rigid routines, for instance exact and narrow timing of the steps involved in
the dental hygiene or getting dressed?
Do certain things belong to a particular place?
Do you prepare lists or schedules? Do you enjoy sorting things? Do these lists/schedules
serve a certain purpose for you or others?
On a scale from 0 to 10, how unpleasant are new situations for you?
Why are new situations unpleasant?
What do you like to do in your leisure time?
On average, how many hours do you spend with a particular topic?
Do you like to engage in certain mental routines like counting steps of a staircase or
extracting roots?
Are there any numbers you particularly like, dislike or that you pay attention to?
Relationships to others Who are the most important people in your life?
Is it difficult for you to get into contact with others?
Why is it difficult to get into contact with others?
Is it difficult to maintain a relationship over a longer period of time?
Why is it difficult to maintain a relationship over a longer period of time?
Do you experience misunderstandings with others very often?
What do you think are the reasons for these misunderstandings?
Would you like to have more contact to others?
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mental history (motor, cognitive and speech development),
current daily functioning and quality of relationships was
performed and used for supporting the autism diagnosis
(for a description of the interview questions see Table 1; de-
tailed psychometrical analysis and validation of this new in-
strument will be provided elsewhere). The PAUSS items
were rated according to the PANSS manual. Moreover, a
33-item version of the Autism Quotient (AQ) and the Em-
pathy Quotient (EQ) self-rating questionnaires were admin-
istered [1,36,37]. Four subtests of the German version of
the Wechsler Adult Intelligence Scale revised (WAIS-R)
were completed to estimate verbal and performance IQ
(comprehension, similarities, picture completion and block
design) [38]. The Global Assessment of Functioning (GAF)
was scored to determine the global functional status of the
participants [11]. ASD diagnoses were confirmed or ex-
cluded according to DSM-IV-TR criteria and to the guide-
line of the United Kingdom’s National Institute for Health
and Care Excellence (NICE). The diagnosis was always
based on the consensus of the two investigators.
As PANSS had not been developed and evaluated for
the assessment of autism-relevant behaviors, construct
and criterion-related validity of the PAUSS were evalu-
ated. To provide convergent validity, ADOS module 4
was scored based on the ‘original algorithm’ relying onthe social interaction and communication domain
[33]. Additionally, criterion-related validity referring
to the quality of differentiation between autistic and
non-autistic individuals should be assessed for the
PAUSS. It is important to note, that always one of the
two examiners administered and scored the ADOS
while the other conducted the semi-structured inter-
view and rated the PAUSS items. Thus, both ratings
were independent of each other and the clinical
diagnosis.
Disease-control sample
Upon exclusion of an ASD diagnosis, alternative DSM-
IV-TR diagnoses were made based on the clinical infor-
mation obtained during the interviews and the medical
reports available. For economic reasons, only a rough
classification into major DSM-IV-TR disease categories
was possible for these cases. All of them were included
in a so-called disease-control sample. In the present
study, the ASD sample is presented as one diagnostic
entity (no distinctions between Asperger’s and autistic
disorders made) along a continuous severity dimension.
Statistical analyses
All statistical analyses were conducted with SPSS
(SPSS Statistics for Windows, Version 17.0. Chicago:
Table 2 Item-item intercorrelation matrix for individual PAUSS items in the schizophrenic GRAS sample (N = 1159;
Cronbach’s alpha: .857)
Blunted
affect
Poor
rapport
Social
withdrawal
Abstract
thinking
Conversation Stereotyped
thinking
Mannerism
(PANSS N1) (PANSS N3) (PANSS N4) (PANSS N5) (PANSS N6) (PANSS N7) (PANSS G5)
Poor rapport (PANSS N3) .668
Social withdrawal (PANSS N4) .574 .577
Abstract thinking (PANSS N5) .472 .452 .303
Conversation (PANSS N6) .577 .598 .573 .432
Stereotyped thinking (PANSS N7) .414 .442 .332 .400 .254
Mannerism (PANSS G5) .263 .244 .218 .245 .137 .315
Preoccupation (PANSS G15) .490 .558 .499 .391 .363 .523 .293
Spearman rank correlation coefficients are shown (N = 1159). All item-item correlations are statistically significant (p-values < .00001). Correlation coefficients ≥ 0.4 are
set in boldface.
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Figure 2 Validation of the PAUSS. (A) Intercorrelations of the PAUSS and ADOS with age and WAIS estimated total IQ (Spearman rank) (B) Intercorrelations
of individual PAUSS items (Spearman rank) and the Autism Diagnostic Observation Schedule (ADOS). (C) Significant differences were obtained for the
PAUSS by ADOS-diagnosis group (ADOS≥ 12: autism; ADOS≥ 7: autism spectrum; ADOS < 7: no autism). (D, E) No significant differences were found for
AQ and EQ by ADOS-diagnosis group. (F) Receiver Operating Characteristic curves for PAUSS and ADOS illustrate high Area under the Curve (AuC) statistics
and thus high predictive power of both instruments. (G) Receiver Operating Characteristic curves for AQ and EQ illustrate low Area under the Curve (AuC)
statistics and thus low predictive power of both instruments. P-values were obtained from analysis of covariance with age and IQ as covariates.
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(GraphPad Software, San Diego California USA, www.
graphpad.com). Spearman rank correlation coefficients
are reported for autism variables in the GRAS sample
(Table 2) and PAUSS, ADOS, age and IQ (Figure 2A)
as well as individual PAUSS items and ADOS (Figure 2B).
In the present study, criterion-related validity refers to the
degree to which ADOS and PAUSS ratings are in
agreement with the clinical diagnosis of having ASD
or not. For the ADOS, the diagnoses based on the ori-
ginal ADOS algorithm module 4 were used: Autism is
diagnosed if a subject scores ≥ 12; autism spectrum
disorder is diagnosed when a score of ≥ 7 is obtained.
Scoring below 7 does not support an ASD diagnosis.
ADOS diagnosis group differences in PAUSS, AQ and
EQ were assessed by analysis of covariance including
covariates age and IQ as they correlated substantially
with the PAUSS (Figure 2C-E). Receiver Operating
Characteristic (ROC) curves were calculated to pro-
vide information on the sensitivity and specificity of
all possible threshold settings for ADOS and PAUSS
(Figure 2F, G). Sensitivity and specificity at all possible
PAUSS cut-offs are provided (Table 3). Area under the
Curve (AuC) statistics representing the overall level of
agreement between criterion (i.e. clinical ASD diagno-
sis) and instrument (i.e. ADOS and PAUSS) were de-
termined. The higher the AuC (1 = perfect agreement),
the higher the probability for a randomly chosen ASD
patient to score higher on the respective instrumentTable 3 PANSS autism severity scores and their correspondin
PANSS autism severity score Sensitivity Specificity
7.0 1.000 0.000
8.5 0.986 0.206
9.5 0.953 0.289
10.5 0.939 0.443
11.5 0.912 0.526
12.5 0.858 0.629
13.5 0.804 0.680*
14.5 0.723 0.711**
15.5 0.696 0.742
16.5 0.635 0.794
17.5 0.608 0.845
18.5 0.534 0.856
19.5 0.500 0.876
20.5 0.446 0.887
21.5 0.385 0.918
22.5 0.351 0.918
23.5 0.297 0.918
*The cut-off of 15 (14.5) yields a sensitivity of 72.3% and a specificity of 71.1%. **When
reduction of specificity to 68%.than a randomly chosen proband without ASD. Group
differences (Tables 4, 5, 6) were assessed by Mann-
Whitney U tests (continuous variables) or Chi-square/
Fisher’s exact test (categorical variables). All p-values
are two-sided. The respective statistical procedures
applied are additionally mentioned in Table footnotes
and Figure legends. Bonferroni multiple testing cor-
rections were performed as indicated there.
Results
PAUSS distribution in the GRAS sample allows for
extreme-group definition
The high internal consistency of the autism variables
(Cronbach’s alpha: .857; Table 2) indicates their measur-
ing one underlying construct (autism). All item-item
correlations were found to be statistically significant (all
p-values < .00001, Table 2). Consequently, single PANSS
items were summed up to reflect the overall severity of
the dimensional trait ‘autism’. The distribution of the
PAUSS in the schizophrenic GRAS sample encouraged
the definition of extreme-groups contrasting maximally
with respect to the PAUSS (first and last percentile,
Figure 1A). Male and female GRAS patients did not
differ on the PAUSS ratings (Figure 1A). Schizophre-
nia patients scoring above the last percentile of the
PAUSS distribution (PAUSS 30-52; referred to as ‘aut-
istic schizophrenia patients’) scored higher than ASD
patients (mean ± SD: 20.5 ± 7.7) who were more se-
verely impaired than non-autistic schizophrenia (firstg sensitivity and specificity values
PANSS autism severity score Sensitivity Specificity
24.5 0.243 0.938
25.5 0.196 0.938
26.5 0.162 0.948
27.5 0.142 0.948
28.5 0.128 0.948
30.0 0.115 0.959
31.5 0.101 0.959
32.5 0.095 0.959
33.5 0.074 0.969
34.5 0.054 0.969
36.0 0.034 0.979
37.5 0.027 0.979
38.5 0.020 0.990
42.0 0.014 1.000
46.0 0.007 1.000
48.0 0.000 1.000
using a cut-off of 14 (13.5) sensitivity is increased to 80.4% at the cost of a
Table 4 Sociodemographic and clinical comparison of autistic and non-autistic schizophrenics (GRAS sample)
Autistic schizophrenia patientsa Non-autistic schizophrenia patientsa
Men Women Men Women
N = 75-80 N = 53-57 N = 86-96 N = 62-72
Sociodemographic variables
Age at examination, mean ± SD, yb 42.1 ± 13.2 49.2 ± 14.5 36.3 ± 11.9 41 ± 10.9*
Ethnicity, No. (%), Caucasianc 76 (95) 53 (98.1) 92 (96.8) 71 (98.6)
Years of education, mean ± SDb 11 ± 2.7 11.2 ± 2.1 13.4 ± 3.1*** 14.2 ± 3.3***
Current occupation, No. (%), full-time workd 5 (6.3) 1 (1.8) 16 (16.8) 11 (15.1)
Marital status, No. (%), singlec 71 (88.8) 31 (54.4) 75 (78.9) 32 (43.8)
Children, No. (%), withoutc 70 (87.5) 28 (49.1) 78 (82.1) 39 (53.4)
Relationship status, No. (%), no relationshipc 67 (83.8) 31 (54.4) 68 (71.6) 26 (35.6)
Clinical variables
Age at first episode, mean ± SD, yb 26.0 ± 9.2 30.8 ± 12.6 25.8 ± 7.2 29.1 ± 9.8
Duration of disease, mean ± SD, yb 16.3 ± 12.9 18.2 ± 14.4 10.6 ± 9.8 12.1 ± 9.6
Chlorpromazine equivalents, mean ± SDb 946 ± 863 972 ± 1321 562.4 ± 567* 401.6 ± 489**
Number of hospitalizations, mean ± SDb 10.8 ± 13 10.7 ± 11.5 5.7 ± 4.8 5 ± 4.6*
Premorbid intelligence, mean ± SD, IQe 95 ± 15 97 ± 13 108 ± 16*** 109 ± 14***
PANSS pos, mean ± SDb 19.4 ± 7 19.3 ± 8 9.1 ± 2.9*** 8.7 ± 2.5***
PANSS neg, mean ± SDb 32.6 ± 4.5 32.4 ± 4.2 8.1 ± 1.2*** 8 ± 1.1***
PANSS gen, mean ± SDb 50.5 ± 11.2 51.5 ± 10.8 20.7 ± 4.9*** 20.7 ± 4.2***
PANSS total, mean ± SDb 102.5 ± 19.1 103.5 ± 18.2 37.9 ± 7.4*** 37.4 ± 6.1***
GAF, mean ± SDb 30 ± 10.9 28.1 ± 9.9 62.2 ± 15.2*** 69.2 ± 14.2***
Multiple testing adjusted significances (Bonferroni: p ≤ 0.003) for comparison of ‘autistic schizophrenia patients’ versus ‘non-autistic schizophrenia patients’ by gender are
shown: * ≤ 0.001, **≤ 0.0001, *** ≤ 0.00001; due to missing data upon phenotyping sample size varies between N= 128-137 in the autistic schizophrenia group and N= 148-168 in
the non-autistic schizophrenia group; aCompare with Figure 1: ‘Autistic schizophrenia patients’ score above or equal to the 10th percentile of the PAUSS distribution (PAUSS
30-52), ‘Non-autistic schizophrenia patients’ score below or equal to the first percentile of the PAUSS distribution (PAUSS 8-10); bMann-Whitney U-Test; cχ2-Test; dFisher’s
exact test; ePremorbid intelligence was estimated by using the ‘Mehrfachwahlwortschatztest’ (MWT, multiple choice verbal comprehension test).
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(mean ± SD: 13.3 ± 6.6) on the PAUSS (Figure 1B). In
terms of sociodemographic and clinical characteristics,
the autistic subgroup of schizophrenia patients
reached an inferior academic level accompanied by a
lower premorbid IQ and had more severe psychopath-
ology and a lower functional status as compared to
non-autistic schizophrenia individuals (Table 4). No
group differences (autistic versus non-autistic schizo-
phrenia patients) were found with regard to age at on-
set and duration of disease (Table 4).
High rate of ASD misdiagnoses in Germany
For PAUSS validation, 265 pre-diagnosed adult ASD
patiens were recruited throughout Germany. By applying a
careful diagnostic procedure (according to DSM-IV-TR cri-
teria) at inclusion in this study, for only 62.3% of patients
an ASD diagnoses could be confirmed. The most frequent
alternative diagnosis was ‘personality disorders’ (9.8%). A
total of 7.2% of the subjects did not fulfil criteria for any
psychiatric disorder. For further relevant differential diag-
noses compare Table 5. While diverging regarding age at
examination, ASD and disease-control patients werecomparable with respect to their intellectual functioning
(Table 5). Moreover, ASD patients had higher PAUSS and
ADOS scores than patients with personality and other psy-
chiatric disorders. Interestingly, ASD and psychotic patients
did not differ in ADOS and PAUSS scores. A higher pro-
portion of ASD patients reported to have no children as
compared to disease-controls. Other sociodemographic
characteristics like marital or relationship status as well as
AQ and EQ were not found to differ between ASD and the
overall disease-control sample (Table 5). Compared to the
group of participants who did not receive a clinical diagno-
sis in our study, a larger proportion of ASD patients was
single, had no children and was less functional (Table 5).
Male and female ASD patients did not differ with respect
to sociodemographic characteristics (Table 6).
Evidence for construct and criterion-based validity of the
PAUSS
Construct validity was assessed by evaluating the conver-
gence between PAUSS and ADOS. As ADOS scores have
been shown to be influenced by age and the intellectual
functioning of a given subject [35], we evaluated correla-
tions of ADOS and PAUSS with age and the estimated total
Table 5 Sociodemographic and clinical comparison of ASD and disease-control samples
ASD
sample
Disease-control sample
Personality
disorders
Psychotic
disorders
Other psychiatric
disordersa
No psychiatric
disorder
Total disease-
control sample
N = 106-
165
N = 19-26 N = 6-13 N = 38-42 N = 17-19 N = 80-100
Sociodemographic
variables
Gender, No. (%), menb 108 (65.5) 21 (80.8) 7 (53.8) 30 (71.4) 12 (63.2) 71 (71)
Age at examination,
mean ± SD, yearsb
32.2 ± 11 39.3 ± 12.8 32.6 ± 10.1 38.7 ± 14.3 38.1 ± 12 37.7 ± 13.1*
Years of education,
mean ± SDb
15.3 ± 4.4 15.9 ± 4.8 12.1 ± 4 16.4 ± 4.1 17 ± 4.6 16 ± 4.5
Current occupation,
No. (%), full-time workb
39 (23.6) 6 (23.1) 0 (0) 13 (31) 9 (47.4) 28 (28)
Marital status, No. (%),
singlec
101 (61.2) 12 (46.2) 8 (61.5) 25 (59.5) 7 (36.8) 52 (52)
Children, No (%), nonec 103 (83.7) 12 (57.1) 6 (85.7) 27 (67.5) 9 (50)* 54 (62.1)**
Relationship status, No.
(%), no relationshipc
68 (41.2) 11 (42.3) 5 (38.5) 23 (54.8) 6 (31.6) 45 (45)
Clinical variables
Wechsler Adult
Intelligence Scale-Revised, IQ
subtest comprehension 116 ± 19 113 ± 13 104 ± 19 114 ± 17 117 ± 14 113 ± 16
subtest similarities 115 ± 16 114 ± 13 101 ± 16 120 ± 20 117 ± 15 116 ± 18
subtest picture completion 107 ± 21 111 ± 18 98 ± 26 107 ± 21 111 ± 13 108 ± 19
subtest block design 109 ± 20 107 ± 18 95 ± 23 110 ± 17 111 ± 17 108 ± 18
estimated verbal IQ 115 ± 16 112 ± 10 103 ± 14 116 ± 18 117 ± 12 114 ± 15
estimated performance IQ 107 ± 18 106 ± 18 96 ± 21 108 ± 18 111 ± 12 107 ± 17
estimated total IQ 111 ± 15 110 ± 12 99 ± 17 112 ± 16 114 ± 11 111 ± 14
GAF, mean ± SDb 71 ± 16.2 75.7 ± 11.2 52.5 ± 13 74.4 ± 14.8 87.6 ± 5.3*** 75.5 ± 15
PANSS autism severity
score, mean ± SDb
20.5 ± 7.7 13.3 ± 3.6*** 24.1 ± 9.6 11.4 ± 3.7*** 9.8 ± 2.2*** 13.3 ± 6.6***
ADOS original algorithm
Module 4, mean ± SDb
11.9 ± 4.2 4.3 ± 4.4*** 10 ± 4.8 2.5 ± 2.8*** 2.9 ± 2.2*** 3.8 ± 3.9***
Autism Quotient (AQ),
mean ± SDb,d
23.5 ± 5.7 24 ± 3.6 20.7 ± 4 23.3 ± 5.7 23.2 ± 5.1 23.4 ± 5.1
Empathy Quotient (EQ),
mean ± SDb,e
17.5 ± 8 17.8 ± 8.3 25.1 ± 8.7 21.2 ± 11.6 15.6 ± 9.3 19.4 ± 17.5
Multiple testing adjusted significances (Bonferroni: p ≤ 0.002) for comparison of each diagnostic group with ASD group are shown: * ≤ 0.001, ** ≤ 0.0001, *** ≤ 0.00001;
due to missing data upon phenotyping, sample size varies between N = 186-265 in the total sample; athis category includes affective disorders, attention deficit disorder,
pervasive developmental disorder not otherwise specified, anxiety disorders, alcohol use disorders; bMann-Whitney U test; cChi-square test; dHigher values correspond to
more autistic traits; eHigher values correspond to more empathy (i.e. less autistic traits).
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age, while only for PAUSS a high correlation with the esti-
mated total IQ was found (Figure 2A). Importantly, ADOS
and PAUSS were found to correlate substantially (r = .763;
Figure 2A; partial correlation coefficient when correcting
for age and IQ: r = .736, data not shown). All single PAUSS
items correlated significantly (p < .00001) with the ADOS
(Figure 2B). Strongest correlations were observed forADOS and ‘blunted affect’, ‘social withdrawal’, ‘conversation’
and ‘preoccupation’. ADOS diagnosis groups diverged
regarding the PAUSS but not regarding AQ and EQ
(Figure 2C-E). Individuals who scored above 12 in the
ADOS obtained highest, those with a score below 7
lowest PAUSS scores. ROC curves for ADOS and
PAUSS resulted in AuC values of 0.916 and 0.824, respect-
ively (Figure 2F). For AQ and EQ, low AuC values were
Table 6 Sociodemographic and clinical comparison of ASD and disease-control samples by gender
ASD sample Disease-control samplea
Men Women p-value Men Women p-value
N = 70-107 N = 37-58 N = 58-71 N = 21-29
Sociodemographic variables
Age at examination, mean ± SD, yearsb 31.3 ± 11.3 34.1 ± 10.3 .050 37.6 ± 13.9 38 ± 11.2 .747
Years of education, mean ± SDb 14.6 ± 4.1 16.5 ± 4.8 .040 15.9 ± 4.4 16.2 ± 4.8 .529
Current occupation, No. (%), full-time workb 25 (23.4) 14 (24.1) 1.00 18 (25.4) 10 (34.5) .462
Marital status, No. (%), singlec 67 (62.6) 34 (58.6) .620 40 (56.3) 12 (41.4) .193
Children, No (%), nonec 68 (86.1) 35 (81.4) .602 42 (66.7) 12 (50) .216
Relationship status, No. (%), no relationshipc 47 (43.9) 21 (36.2) .408 35 (49.3) 10 (34.5) .192
Clinical variables
Wechsler Adult Intelligence Scale-Revised, IQ
subtest comprehension 117 ± 20 115 ± 18 .396 113 ± 17 114 ± 12 .949
subtest similarities 114 ± 17 117 ± 13 .465 116 ± 18 117 ± 18 .705
subtest picture completion 105 ± 23 113 ± 17 .072 108 ± 20 107 ± 18 .728
subtest block design 108 ± 22 110 ± 17 .711 108 ± 18 108 ± 17 .643
estimated verbal IQ 115 ± 17 116 ± 13 .937 114 ± 16 115 ± 13 .825
estimated performance IQ 106 ± 20 111 ± 15 .143 107 ± 18 108 ± 15 .851
estimated total IQ 110 ± 17 113 ± 12 .302 111 ± 16 111 ± 12 .837
GAF, mean ± SDb 69.4 ± 17.1 74 ± 14.2 .191 75.1 ± 14.7 76.5 ± 15.8 .509
PANSS autism severity score, mean ± SDb 20.3 ± 7.7 20.1 ± 7.5 .842 13.3 ± 6.5 13.5 ± 6.7 .597
ADOS original algorithm Module 4, mean ± SDb 11.9 ± 4.1 12 ± 4.3 .962 3.9 ± 4 3.4 ± 3.8 .691
Autism Quotient (AQ), mean ± SDb,d 22.3 ± 5.9 25.6 ± 4.7 .006 22.8 ± 5.3 25 ± 4.2 .071
Empathy Quotient (EQ), mean ± SDb,e 18.6 ± 8 15.4 ± 7.6 .044 20.4 ± 10.2 16.7 ± 10.5 .108
Multiple testing adjusted significances (Bonferroni: p ≤ 0.002) for comparison of each diagnostic group with ASD group are shown: due to missing data upon
phenotyping, sample size varies between N = 186-265 in the total sample; athis category includes affective disorders, attention deficit disorder, pervasive developmental
disorder not otherwise specified, anxiety disorders, alcohol use disorders; bMann-Whitney U test; cChi-square test; dHigher values correspond to more autistic traits;
eHigher values correspond to more empathy (i.e. less autistic traits).
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higher ADOS and PAUS scores predicted a higher prob-
ability of having a clinical ASD diagnosis whereas AQ and
EQ performed at chance level. Cut-off scores and their re-
spective sensitivities and specificities are provided (Table 3).
Taken together, evidence for the PAUSS to measure autism
relevant traits could be obtained.Discussion
A multitude of genetic and clinical studies converge on
the notion that similar biological pathways may be in-
volved in the etiology of autism and a subgroup of
schizophrenia patients [23,39]. Selected items from a
clinical rating instrument developed to assess schizo-
phrenia psychopathology (PANSS) were aggregated to
characterize autistic symptoms in the GRAS sample of
schizophrenic patients (PAUSS). The PAUSS was vali-
dated in ASD and disease-control samples. PAUSS and
ADOS correlated substantially. Moreover, the PAUSS
differentiated between autism (individuals with ASD andautistic schizophrenia subjects), other psychiatric disor-
ders and healthy subjects.
Interestingly, the autistic schizophrenia subgroup had
higher PAUSS values than the ASD sample. This might be
due to the fact that only high-functioning ASD patients, in-
cluding Asperger’s disorder and autistic disorder patients
with average intellectual functioning, were included in the
present study (GAF 71, estimated total IQ 111). For the
autistic subgroup of schizophrenia subjects functional sta-
tus and IQ were considerably lower (GAF 31; premorbid
IQ 95), and also lower as compared to the non-autistic
schizophrenia subjects (GAF 63, premorbid IQ 108). This
could point to a generally more affected patient sample
where PAUSS items reflect the general psychopathology on
top of autism-related features.
Over one third of the patients diagnosed or suspected
to have autism by healthcare professionals turned out to
have a different or no psychiatric diagnosis. Consistent
with other reports, common differential diagnoses in the
present study were personality and affective disorders
[40]. The low reliability of ASD diagnoses in adults may
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procedure for ASD in adults in Germany [26,41]. Special
outpatient centers for ASD in adulthood and specialized
practicing psychiatrists are scarce. Owing to the increas-
ing public interest in ASD and the growing demand of
diagnostic evaluation [42-44], the procedure has to be
efficient. This will enable timely initiation of adequate
therapeutic interventions for ASD patients as well as for
individuals with other psychiatric disorders. AQ and EQ
are often used as screening instruments because they
are time-efficient [40]. However, given the broadly im-
paired introspective capacities of individuals with ASD
(e.g. self-referential cognition and empathy) [45,46] and the
different degrees of self-evaluation skills acquired by train-
ing, in the present study, self-assessment (AQ and EQ) did
not differentiate between ASD and differential diagnoses
nor did it correlate with ADOS and PAUSS. The PAUSS in
turn may be further psychometrically validated to evolve as
a rapid, easy to apply and valid screening instrument ultim-
ately complementing the ADOS.
The findings of the present study are well in line with
a previous study illustrating that some patients with
treatment-resistant schizophrenia have autistic symp-
toms and that these co-vary with negative but not with
positive symptoms [47]. Notably, this subgroup of pa-
tients did not respond to antipsychotic treatment. Neur-
exin1 (NRXN1) is among the genes associated with both
ASD and schizophrenia [48,49]. Accumulating evidence
reveals that certain NRXN1 genotypes are overrepre-
sented among non-responders to antipsychotic treat-
ment [50-52]. These reports exemplify the involvement
of biological pathways not targeted by conventional
dopaminergic agents in a subgroup of schizophrenia pa-
tients that likely represents the autistic subgroup.
Prospective research will have to consider whether the
phenotypical overlap between autism and schizophrenia
shown here indicates that both conditions can emerge from
related neurodevelopmental vulnerabilities or shared patho-
genic mechanisms based on genotypical overlap [13-15]. It
may also address the question whether autism and schizo-
phrenia share other phenotypical aspects, such as neuro-
anatomical similarities.Conclusions
The present work highlights the remarkable convergence
of schizophrenia negative symptomatology and autistic
features. It shows that the PAUSS correlates substantially
with the ADOS. Additionally, the PAUSS is able to dis-
criminate ASD patients from disease controls. This lends
support to the fact that the PAUSS is suitable for the di-
mensional assessment of autistic behaviors in schizo-
phrenia and high-functioning autism. The definition of
extreme-groups based on the dimensional PAUSS maypermit future investigations of genetic constellations
modulating autistic phenotypes.
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